Navigation Links
Genaera Receives Non-Compliance Notice from Nasdaq
Date:5/27/2009

PLYMOUTH MEETING, Pa., May 27 /PRNewswire-FirstCall/ -- Genaera Corporation ("the Company") (Nasdaq: GENR) today announced that it has received notification from Nasdaq stating that Genaera is no longer in compliance with Nasdaq Marketplace Rule 5250(c)(1) for continued listing because the Company has not yet filed its Form 10-Q for the period ended March 31, 2009. Under Nasdaq rules, the Company has 60 calendar days from the date of the Nasdaq notification letter to submit a plan to regain compliance with Nasdaq's continued listing requirements.

Genaera previously announced on April 28, 2009 that its Board of Directors approved a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution"), subject to stockholder approval. The Company intends to hold a special meeting of stockholders on June 4, 2009 to seek approval of the Plan of Dissolution and has filed definitive proxy materials with the Securities and Exchange Commission ("SEC"). If stockholder approval of the Plan of Dissolution is obtained at the special meeting, the Company intends to file a certificate of dissolution and delist its common stock from Nasdaq.

About Genaera

Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our Web site at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assu
'/>"/>

SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces 2007 Financial Results
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation to Present at BIO Business Forum
8. Genaera Corporation Elects Paul K. Wotton to Board of Directors
9. Genaera Corporation Announces Second Quarter Financial Results
10. Genaera to Present at BIO-Europe 2008
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...0 Novavax, Inc. (Nasdaq:...ed today that the company will be presenting at th...ber 2, 2009 at 12:30 pm local time at The New York...ew of the company,s business strategy, research an... link to the live audio only presentation can be a...
(Date:11/30/2009)...wire/ -- Dr. Jessica Torrente, Assistant Professor...cal Center in Washington, D.C., demonstrated the i...g (BSGI) in clinical practice as an adjunct imagin...y at the annual meeting of the Radiological Societ...he exhibit was to demonstrate how BSGI is used in ...
(Date:11/30/2009)... BioMarin Pharmaceutical ...d and Drug Administration (FDA) has granted orphan...), amifampridine phosphate, for the rare autoimmun.... 3,4-DAP has previously received orphan drug des...ommittee for Medicinal Products for Human Use of t...
(Date:11/30/2009)..., Nov. 30 Exiqon A/S (NASDAQ OMX C... Medical School ICCB-Longwood Screening Facility (...g Center of Excellence. ICCB-L supports investiga...pitals and institutions, for high-throughput scree...icroRNAs are a novel class of small, non-coding RN...
Breaking Biology Technology:NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3
...7 The market for congestive heart,failure (CHF) d...7, and is,expected to reach $30 billion by 2017, a...Congestive Heart Failure: Major World Markets, Vol...driven by three factors: an,increased incidence of...n,search of targeted therapies which is creating o...
...ril 17 Spherix Incorporated,(Nasdaq: SPEX ) anno...perations. Mr. Brown will be monitoring and overse...rial regarding the use of Naturlose(R) as a,treatm...as allowed Spherix,to terminate its agreement with...r full control of the clinical trial and its pivot...
...7 SPO Medical Inc. (OTC:,SPOM), a leading develop...r,use in portable monitoring devices, today announ...Capital Ventures (ACV), a leading provider of,comp... cap community, as an,investor relations consultan...ve Officer of SPO Medical,commented, "As we contin...
Other Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Spherix Hires Key Employees 2SPO Medical Retains American Capital Ventures for Investor Relations Services 2SPO Medical Retains American Capital Ventures for Investor Relations Services 3
(Date:11/26/2009)...ies has shown that closing schools in the event of...ficant role in reducing illness transmission. Rese...fectious Diseases compared opportunities for infe...g that they were reduced when schools are shut. ,...Belgium, led a team of European researchers in usi...
(Date:11/25/2009)...ay be used to boost resistance to, or slow, the de...edicine researchers report in a study published in..., Parkinson,s disease is caused by a degeneratio...nown as the substantia nigra, which is responsible...opamine in late-stage Parkinson,s causes symptoms ...
(Date:11/25/2009)...s some 250 million liters of blood through the bod...he heart have to be extremely durable. The researc...ir of the Department of Medicine III at Heidelberg...tus), has discovered a protein that is responsible...the sarcomere. In cooperation with other researche...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 1Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 9GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 1GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 2GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 3Opto electronic nose sniffs out toxic gases 9902 1Opto electronic nose sniffs out toxic gases 9902 2Opto electronic nose sniffs out toxic gases 9902 3
...ghting like a girl or fighting like a boy is hardw...in the Nov. 19 Nature Neuroscience advance online ...l School and the Institute of Molecular Pathology ...s "fruitless" is a key factor underlying sexual di...ne in an unlikely new animal model for understandi...
...e Shoklo Malaria Research Unit (SMRU), Thailand, w...28 December entitled "Twenty Years of Malaria Rese...nationally-renowned experts and featuring talks an...a, from epidemiology to therapeutics and from immu...Research Unit (SMRU) in Mae Sot, Thailand, which b...
...searchers at the Albert Einstein College of Medici...n grant from the National Cancer Institute to stud...t with surrounding tissues, cells and chemicals in... invade other areas of the body in the process kno...ohn Condeelis, co-chair of anatomy and structural ...
Other Biology News:Fighting like a girl or boy determined by gene in fruit flies 2Fighting like a girl or boy determined by gene in fruit flies 3Twenty Years of Malaria Research: Outcomes and Perspectives 2World's smallest cancer detection device 2
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
...r routine procedures. Hollandes contains formaldeh...l decalcify small bone specimens. Tissue that is f...ith most stains, and the cupric acetate in the sol...nophil and endocrine cell granules so that less ly...
...tograph/Mass Spectrometer, utilizing many of the h...igh throughput and excellent productivity, providi...io. Like the GCMS-QP2010 Plus, the GCMS-QP2010s fe...um separation, 20 temperature ramps, and both scan...
Biology Products: